Flying Health pioneers next generation healthcare

Made of bits and bytes

At Flying Health we’re paving the way for next generation healthcare. With our Pioneer Program for corporate partners and focus as an innovative digital biotech company developing Digital Drugs, we are firmly at the forefront of tomorrow’s healthcare.

The Flying Health Pioneer Program helps industry leaders and startups navigate the healthcare field, providing them with experienced corporate foresight for their business and the next generation of healthcare.

We are a Digital Biotech company with a growing pipeline of Digital Drugs. These drugs – made up of bits and bytes – have the potential to help humans live better.

Our Offer

For Corporates

Our Pioneer Program allows us to work closely with industry leaders as they find their footing in the digital healthcare field.
All of our partners are dedicated innovation drivers. We provide an ecosystem for trailblazers, offering knowledge, a well-connected network and an inclination towards execution: we want the business of tomorrow to happen today.
We constantly screen the market to detect early signals of future trends in healthcare and other industries. We connect the right people on projects and collaborations. Are you interested in hearing more about the Pioneer Program? Write to us at

Our Offer

For Strategic Partners and Investors

We are a digital biotech company developing a growing portfolio of Digital Drugs. A Digital Drug is a purely software-generated medical stimulus that triggers a direct physiological response. In short: your medicine is now on your phone. Digital Drugs address the causes of a disease rather than the symptoms, typically through training, stimulating or modulating specific parts of the nervous system. We believe Digital Drugs have the potential to innovatively treat a lot of illnesses. Our products are medically proven and developed by scientists with high ethical standards. For now, our areas of focus for Digital Drugs are ophthalmology, immunology and mental and neurological diseases. We’re looking for strategic partners and investors to develop new products and enhance our pipeline. If you want to find out more about a partnership, write to us at

Our references


Our references